Compare TG Therapeutics Inc (TGTX) vs United Parcel Service Inc (UPS) Price & Performance

TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.

The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.

UPS stock trades at $94.44, up 2.34% today, amid mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company shows stable profitability with 5.08% net margin and 29.66% ROE, though revenue has declined from $100.3B in 2022 to $88.66B in 2025. Recent Q2 2026 earnings beat expectations at $1.76 EPS versus $1.65 expected. Analyst sentiment is divided with 47% Buy ratings and a $118.67 consensus target, while recent news highlights margin pressures and competitive threats from Amazon.

The investment outlook for UPS balances attractive valuation (P/E 17.5, below industry average) and strong dividend yield near 7% against declining revenue trends and rising debt-to-asset ratio (33.02% in 2025). Key risks include domestic volume weakness, fuel cost pressures, and Amazon competition, but strategic initiatives like the TikTok Shop partnership and Secure Commerce platform offer growth potential. Wall Street's neutral-to-buy stance suggests cautious optimism for margin recovery.